<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article299</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/HERA" style="display:block; margin-bottom:10px;">HERA Original</a></li>
<h2><strong>HERA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Trastuzumab for HER2-Positive Early Breast Cancer". The New England Journal of Medicine. 2005. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
    6.1 Inclusion Criteria<br/>
    6.2 Exclusion Criteria<br/>
7 Interventions<br/>
8 Outcomes<br/>
    8.1 Primary Outcome<br/>
    8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with HER2-positive early-stage breast cancer who have completed locoregional therapy and chemotherapy, does trastuzumab therapy improve disease-free survival?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
A year of trastuzumab therapy after adjuvant chemotherapy significantly improves disease-free survival amongst women with HER2-positive early-stage breast cancer.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Trastuzumab is now a standard part of treatment for HER2-positive early breast cancer following primary treatment based on these trial results.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- International, multicenter, randomized, open-label trial<br/>
- N=5,081 patients with HER2-positive early-stage invasive breast cancer<br/>
- Trastuzumab for 1 year (n=1,694) vs. Observation (n=1,693)<br/>
- Enrollment: December 2001 to March 2005<br/>
- Mean follow-up: 1 year<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Women with early-stage invasive breast cancer with overexpressed or amplified HER2 after locoregional therapy and at least four cycles of chemotherapy<br/>
- Median age: 49 years<br/>
<br/>
Inclusion Criteria<br/>
- Histologically confirmed invasive breast cancer with overexpression or amplification of HER2<br/>
- Completed locoregional therapy<br/>
- At least four cycles of chemotherapy<br/>
- Adequate baseline organ function<br/>
<br/>
Exclusion Criteria<br/>
- Distant metastases<br/>
- Previous invasive breast carcinoma<br/>
- Previous neoplasm not involving the breast<br/>
- Clinical stage T4 tumor or involvement of supraclavicular nodes<br/>
- LVEF &lt; 55%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Trastuzumab: 8 mg/kg IV once, followed by 6 mg/kg IV every three weeks for one year<br/>
- Observation: No trastuzumab administration<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Disease-free survival, defined as time from randomization to the first occurrence of breast cancer recurrence, contralateral or ipsilateral cancer, second nonbreast cancer, or death from any cause<br/>
<br/>
Secondary Outcomes<br/>
- Cardiac safety, overall survival, site of the first disease-free survival event, time to distant recurrence<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Short follow-up period<br/>
- Potential long-term risks of cardiotoxicity are unknown<br/>
- Unclear if trastuzumab effectively reduces incidence of disease recurrence in the central nervous system<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Supported by F. Hoffmann–La Roche (Roche), Basel, Switzerland<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- [Related articles and publication details provided by The New England Journal of Medicine]
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
